User contributions for Alara E. Dagsali

Results for Alara E. Dagsali talk block log uploads logs
A user with 143 edits. Account created on 21 August 2023.
Jump to navigation Jump to search
Search for contributionsExpandCollapse
⧼contribs-top⧽
⧼contribs-date⧽
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

10 April 2025

  • 11:5311:53, 10 April 2025 diff hist +14,877 N Givinostat Hydrochloride Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=givinostat |aOrAn=an |drugClass=inhibits class I and class II histone deacetylases (HDACs) and several pro-inflammatory cytokines |indicationType=treatment |indication=of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. |adverseReactions=*Hematological Changes *Increased Triglycerides *Gastrointestinal Disturbances *QTc Prolongation |blackBoxWarningTitle='..." current
  • 10:3310:33, 10 April 2025 diff hist +18,496 N Sotatercept-csrk Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName= Alara Ece Dagsali, M.D. |aOrAn=an |drugClass=activin signalling inhibitor |indicationType=treatment |indication=of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. |adverseReactions=*Erythrocytosis *Severe Thr..." current
  • 06:0306:03, 10 April 2025 diff hist +16,208 N Nogapendekin alfa inbakicept-pmln Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=nogapendekin alfa inbakicept-pmln |aOrAn=an |drugClass=interleukin-15 (IL-15) receptor agonist |indicationType=treatment |indication=of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. |adverseReactions=The most common (≥15%) adverse reactions, were increased creatinine, dysuria, hematuri..." current

20 March 2025

18 March 2025

  • 20:5820:58, 18 March 2025 diff hist +29,524 N Danicopan Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Danicopan |aOrAn=a |drugClass=medication |indicationType=treatment |indication=VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). |hasBlackBoxWarning=Yes |adverseReactions=*Serious Infections Caused by Encapsulated Bacteria *Hepatic Enzyme Increase *Hyperl..." current
  • 20:3920:39, 18 March 2025 diff hist +69 Alara E. Dagsali No edit summary current Tag: Visual edit: Switched
  • 20:3620:36, 18 March 2025 diff hist +36,115 N Ceftobiprole medocaril sodium Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=ceftobiprole medocaril sodium |aOrAn=a |drugClass=beta-lactam class of antibiotics |indicationType=treatment |indication='''1.1 Staphylococcus aureus Bloodstream Infection (Bacteremia)''' ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by me..." current
  • 19:5019:50, 18 March 2025 diff hist +96 Pegulicianine No edit summary current
  • 19:4819:48, 18 March 2025 diff hist +17,199 N Pegulicianine Created page with "{{DrugProjectFormSinglePage |authorTag=User:AED |genericName=pegulicianine |aOrAn=a |drugClass=diagnostic imaging agent |indicationType=diagnosis |indication=LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. |hasBlackBoxWarning=Yes |adverseReactions=*Anaphylaxis and Other Serious Hyp..."

6 March 2025

4 March 2025

17 December 2024

16 May 2024

  • 07:0707:07, 16 May 2024 diff hist +21 User:AED No edit summary current
  • 07:0607:06, 16 May 2024 diff hist +3 Diclofenac Patch No edit summary current
  • 07:0607:06, 16 May 2024 diff hist +48,610 N Diclofenac Patch Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=DICLOVIX |indicationType=treatment |indication=Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). |hasBlackBoxWarning=Yes |adverseReactions=Dry Skin (Application Site) Contact Dermatitis (Application Site) Dyspepsia Abdominal Pain Flatulence Pruritus (Application Site) Diarr..."
  • 06:4206:42, 16 May 2024 diff hist +24 User:AED No edit summary
  • 06:4206:42, 16 May 2024 diff hist +3 Cortisone Acetate No edit summary current
  • 06:4206:42, 16 May 2024 diff hist +14,095 N Cortisone Acetate Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Cortisone Acetate |aOrAn=a |indicationType=treatment |indication=When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congen..."
  • 06:3306:33, 16 May 2024 diff hist +27 User:AED No edit summary
  • 06:3306:33, 16 May 2024 diff hist +3 Clocortolone Pivalate No edit summary current
  • 06:3206:32, 16 May 2024 diff hist +4,443 N Clocortolone Pivalate Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Clocortolone Pivalate |indicationType=treatment |indication=Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. |adverseReactions=The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed..."
  • 06:2206:22, 16 May 2024 diff hist +30 User:AED No edit summary
  • 06:2106:21, 16 May 2024 diff hist +30 Scorpion No edit summary current
  • 06:2006:20, 16 May 2024 diff hist +12,418 N Scorpion Created page with "{{DrugProjectFormSinglePage |genericName=Anascorp |indicationType=treatment |indication=ANASCORP® [centruroides (scorpion) immune F(ab')2 (equine) injection] is an equine-derived antivenom indicated for treatment of patients with clinical signs of scorpion envenomation. |adverseReactions=The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for ANASCORP were: vomiting, pyrexia, rash, nausea and pruritus. |fdaLIADAdult=For Intravenous u..."

15 May 2024

  • 10:5910:59, 15 May 2024 diff hist +3 Lodoxamide No edit summary current
  • 10:5810:58, 15 May 2024 diff hist +6,534 N Lodoxamide Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve..."

30 April 2024

  • 18:5818:58, 30 April 2024 diff hist +20 User:AED No edit summary
  • 18:5818:58, 30 April 2024 diff hist +3 Isosulfan Blue No edit summary current
  • 18:5718:57, 30 April 2024 diff hist +5,959 N Isosulfan Blue Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape..."
  • 18:4718:47, 30 April 2024 diff hist +22 User:AED No edit summary
  • 18:4718:47, 30 April 2024 diff hist +3 Ibuprofen Lysine No edit summary current
  • 18:4618:46, 30 April 2024 diff hist +15,663 N Ibuprofen Lysine Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc..."
  • 18:2818:28, 30 April 2024 diff hist +20 User:AED No edit summary
  • 18:2818:28, 30 April 2024 diff hist +3 Prussian blue No edit summary current
  • 18:2718:27, 30 April 2024 diff hist +14,067 N Prussian blue Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R..."
  • 18:1518:15, 30 April 2024 diff hist +23 User:AED No edit summary
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)
Retrieved from "https://www.wikidoc.org/index.php/Special:Contributions/Alara_E._Dagsali"